• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.

作者信息

Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenbjerg S, Knudsen J B

机构信息

University Department of Paediatrics, Rigshospitalet, Copenhagen, Denmark.

出版信息

Thromb Haemost. 1987 Dec 18;58(4):1049-52.

PMID:3127918
Abstract

Eleven severely affected haemophilia A patients (aged 6-42 y) with F VIII:C inhibitor (high responders) were treated with high-dose F VIII in order to eliminate the inhibitors. The patients comprise Danish high responder patients treated during the period 1977-1985. In all patients the inhibitors decreased significantly. In six, the inhibitor apparently disappeared (detection limit 0.4 Bethesda Units per ml) (BU/ml), in four patients a low level inhibitor of 0.4-1.4 BU/ml persisted. One patient is still on high-dose schedule. The duration of high-dose treatments ranged from less than one month up to 18 months. In all patients the tendency to spontaneous bleedings vanished when a measurable VIII:C level appeared in the post-infusion sample. The inhibitor suppression has allowed for extensive physical training and rehabilitation orthopaedic surgery. The patients are now able to conduct a normal haemophilic life on self-administered prophylactic doses of F VIII.

摘要

相似文献

1
Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: a description of eleven patients treated.
Thromb Haemost. 1987 Dec 18;58(4):1049-52.
2
[Suppression of factor VIII inhibitor in children with hemophilia A].
Padiatr Padol. 1987;22(4):345-52.
3
[Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].[通过定期输注凝血因子 VIII 在高反应性抑制物的甲型血友病患者中成功诱导免疫耐受及产生新型止血效果]
Rinsho Ketsueki. 1996 Nov;37(11):1303-8.
4
Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.低剂量免疫耐受诱导用于患有VIII因子抑制物的儿科血友病患者。
Haemophilia. 2008 Mar;14(2):315-22. doi: 10.1111/j.1365-2516.2007.01621.x. Epub 2007 Dec 10.
5
Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.在高反应不良风险的血友病A抑制物患者中,使用高纯度血管性血友病因子/ VIII复合物浓缩物诱导免疫耐受。
Haemophilia. 2007 Jul;13(4):373-9. doi: 10.1111/j.1365-2516.2007.01484.x.
6
Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.成功诱导低剂量免疫耐受治疗严重血友病 A 伴低于 40 贝塞斯达单位抑制剂
Haemophilia. 2010 May;16(102):71-9. doi: 10.1111/j.1365-2516.2010.02225.x.
7
Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
Haematologica. 2000 Oct;85(10 Suppl):73-4.
8
Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.获得性凝血因子 VIII 同种抗体血友病 A 患者的免疫耐受治疗:单一机构经验的综合分析
Thromb Haemost. 1999 Jan;81(1):35-8.
9
Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.尽管该治疗预后不佳,但对于一名患有先天性血友病且凝血因子 VIII 抑制物效价高的患者,使用高剂量凝血因子 VIII 和静脉注射免疫球蛋白成功诱导了免疫耐受。
Med Sci Monit. 2009 Jun;15(6):CS105-11.
10
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.轻度和中度血友病A中的凝血因子VIII抑制剂。英国血友病中心主任组织。
Thromb Haemost. 1998 Apr;79(4):762-6.

引用本文的文献

1
Final Results of the Prospective ADVATE Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII.前瞻性无血浆和无白蛋白重组因子VIII的ADVATE免疫耐受诱导注册研究(PAIR)的最终结果。
J Blood Med. 2021 Nov 20;12:991-1001. doi: 10.2147/JBM.S329883. eCollection 2021.
2
Clinical experience with Hemofil M in a hemophilia patient exhibiting inhibitors.在一名出现抑制物的血友病患者中使用Hemofil M的临床经验。
Ann Hematol. 1991 Sep;63(3):152-4. doi: 10.1007/BF01703247.